IL-1 antagonist formulations
US7365165B2 · kind B2 · utility
3Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2005 |
| Grant date | Apr 29, 2008 |
| Priority date | — |
| Expiry date | Jan 12, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. Most preferably, the fusion protein has the sequence of SEQ ID NO:10.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.